1. Home
  2. MLGO vs BTAI Comparison

MLGO vs BTAI Comparison

Compare MLGO & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MicroAlgo Inc.

MLGO

MicroAlgo Inc.

HOLD

Current Price

$3.72

Market Cap

38.4M

Sector

Technology

ML Signal

HOLD

Logo BioXcel Therapeutics Inc.

BTAI

BioXcel Therapeutics Inc.

HOLD

Current Price

$1.47

Market Cap

35.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MLGO
BTAI
Founded
2018
2017
Country
China
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
38.4M
35.6M
IPO Year
2020
2018

Fundamental Metrics

Financial Performance
Metric
MLGO
BTAI
Price
$3.72
$1.47
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$25.33
AVG Volume (30 Days)
122.4K
818.8K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$87,132,230.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$261.81
P/E Ratio
$0.91
N/A
Revenue Growth
6.21
N/A
52 Week Low
$0.50
$1.17
52 Week High
$32.40
$8.08

Technical Indicators

Market Signals
Indicator
MLGO
BTAI
Relative Strength Index (RSI) 43.33 40.90
Support Level $0.53 $1.50
Resistance Level $4.83 $2.28
Average True Range (ATR) 0.27 0.11
MACD 0.07 0.00
Stochastic Oscillator 47.96 8.57

Price Performance

Historical Comparison
MLGO
BTAI

About MLGO MicroAlgo Inc.

MicroAlgo Inc is divided into two segments: Central processing algorithm services & Intelligent chips and services. The majority is from the Central Processing Algorithm Services. which refers to a range of computing algorithms, analytical algorithms, recommendation algorithms, & acceleration algorithms. The businesses engaged in internet advertisement, game development, intelligent chip design, finance, retail, & logistics depend on the ability to process & analyze data with optimized computing software & hardware capable of handling the data workload. Intelligent chips and services revenues include revenues generated from the resale of intelligent chips. All of the Company's net revenues were generated in the PRC, Hong Kong, & Singapore, out of which the majority is from the PRC.

About BTAI BioXcel Therapeutics Inc.

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

Share on Social Networks: